Prevalence and associations for abnormal bleeding times in patients with renal insufficiency

References

• Burns ER, Lawrence C. Bleeding time. A guide to its diagnostic and clinical utility. Arch Pathol Lab Med 1989; 113(11)1219–1224
   PubMed Web of Science ®Google Scholar
• Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16(1)1–20
   PubMed Web of Science ®Google Scholar
• Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer – PFA-100. Semin Thromb Hemost 1995; 21(Suppl. 2)106–112
   PubMed Web of Science ®Google Scholar
• Harrison P, Robinson MS, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coagul Fibrinol 1999; 10(1)25–31
   PubMed Web of Science ®Google Scholar
• Morgagni G, Opera Omnia. Ex Typographia Remondiniana 1764, Venezia
   Google Scholar
• Sohal AS, Gangji AS, Crowther MA, Treleaven D. Uremic bleeding: Pathophysiology and clinical risk factors. Thromb Res 2006; 118(3)417–422
   PubMed Web of Science ®Google Scholar
• Rees DD, Palmer RM, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA 1989; 86(9)3375–3378
   PubMed Web of Science ®Google Scholar
• Weigert AL, Schafer AI. Uremic bleeding: Pathogenesis and therapy. Am J Med Sci 1998; 316(2)94–104
   PubMed Web of Science ®Google Scholar
• Noris M, Benigni A, Boccardo P, Aiello S, Gaspari F, Todeschini M, Figliuzzi M, Remuzzi G. Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney Int 1993; 44(2)445–450
   PubMed Web of Science ®Google Scholar
• Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evidence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007; 3(3)138–153
   PubMedGoogle Scholar
• Cho YU, Jang S, Park CJ, Chi HS. Variables that affect platelet function analyzer-100 (PFA-100) closure times and establishment of reference intervals in Korean adults. Ann Clin Lab Sci 2008; 38: 247–253
   PubMed Web of Science ®Google Scholar
• Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 2011; 162: 548–554
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2, Suppl. 1)S1–S266
   PubMed Web of Science ®Google Scholar
• Remuzzi G. Bleeding in renal failure. Lancet 1988; 1(8596)1205–1208
   PubMed Web of Science ®Google Scholar
• Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis 1985; 15(6)357–362
   PubMedGoogle Scholar
• Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Characterization of an in vitro platelet function analyser, PFA-100TM. Clin Appl Thromb Hemost 1996; 2: 241
   Web of Science ®Google Scholar
• Mammen EF, Comp PC, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: A new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998; 24(2)195–202
   PubMed Web of Science ®Google Scholar
• Kim HJ, Kim KM, Koo TY, Chi HS, Kim SH, Kim SB. Prevalence of abnormal in vitro closure time using the Platelet Function Analyzer-100 in chronic kidney disease patients and analysis of associated factors. Clin Nephrol 2011; 76(3)195–200
   PubMed Web of Science ®Google Scholar
• Zupan IP, Sabovic M, Salobir B, Ponikvar JB, Cernelc P. Utility of in vitro closure time test for evaluating platelet-related primary hemostasis in dialysis patients. Am J Kidney Dis 2003; 42(4)746–751
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: A review of analytical variables, benefits and limitations. Haemophilia 2001; 7(2)170–179
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Clinical application of the PFA-100. Curr Opin Hematol 2002; 9(5)407–415
   PubMed Web of Science ®Google Scholar
• Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. 1957. J Am Soc Nephrol 2000; 11(3)589–590; discussion 589–591
   PubMedGoogle Scholar
• Martin W, Villani GM, Jothianandan D, Furchgott RF. Blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation of rabbit aorta by certain ferrous hemoproteins. J Pharmacol Exp Ther 1985; 233(3)679–685
   PubMed Web of Science ®Google Scholar
• Vincelot A, Nathan N, Collet D, Mehaddi Y, Grandchamp P, Julia A. Platelet function during pregnancy: An evaluation using the PFA-100 analyser. Br J Anaesth 2001; 87(6)890–893
   PubMed Web of Science ®Google Scholar
• Escolar G, Cases A, Vinas M, Pino M, Calls J, Cirera I, Ordinas A. Evaluation of acquired platelet dysfunctions in uremic and cirrhotic patients using the platelet function analyzer (PFA-100): Influence of hematocrit elevation. Haematologica 1999; 84(7)614–619
   PubMed Web of Science ®Google Scholar
• Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985; 79(5)552–559
   Google Scholar
• Rabiner SF, Molinas F. The role of phenol and phenolic acids on the thrombocytopathy and defective platelet aggregation of patients with renal failure. Am J Med 1970; 49(3)346–351
   PubMed Web of Science ®Google Scholar
• Aiello S, Noris M, Remuzzi G. Nitric oxide synthesis and L-arginine in uremia. Miner Electrolyte Metab 1997; 23(3–6)151–156
   PubMedGoogle Scholar
• Noris M, Remuzzi G. Uremic bleeding: Closing the circle after 30 years of controversies?. Blood 1999; 94(8)2569–2574
   PubMed Web of Science ®Google Scholar
• Simon DI, Stamler JS, Loh E, Loscalzo J, Francis SA, Creager MA. Effect of nitric oxide synthase inhibition on bleeding time in humans. J Cardiovasc Pharmacol 1995; 26(2)339–342
   PubMed Web of Science ®Google Scholar
• Descamps-Latscha B, Herbelin A, Nguyen AT, Roux-Lombard P, Zingraff J, Moynot A, Verger C, Dahmane D, de Groote D, Jungers P, et al. Balance between IL-1 beta, TNF-alpha, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol 1995; 154(2)882–892
   PubMed Web of Science ®Google Scholar
• Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B. Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor alpha. Kidney Int 1990; 37(1)116–125
   PubMed Web of Science ®Google Scholar